Bristol SEC inquiry
Executive Summary
SEC wholesaler inventory inquiry "may become a more formal investigation," Bristol-Myers Squibb says in 10-Q filed with the Securities & Exchange Commission Aug. 14. "One possible outcome could be a restatement of our results reflecting the previously disclosed wholesaler inventory buildup." Bristol has already restated the estimated impact from excess inventories three times; the most recent estimate implies a revenue impact of nearly $5 bil. (1"The Pink Sheet" July 29, In Brief). "We believe our accounting treatment for the wholesaler inventory buildup was appropriate and, accordingly, believe that this outcome is unlikely"...
You may also be interested in...
Bristol accounting
SEC opens a formal inquiry into Bristol-Myers Squibb's accounting practices related to wholesaler inventory levels (1"The Pink Sheet" Aug. 19, In Brief)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.